Adjuvant trastuzumab 'no benefit' in HER2 oesophageal cancer
The monoclonal antibody did not improve disease-free survival, clinicians say
Adding trastuzumab to neoadjuvant chemoradiation for human epidermal growth factor receptor 2-overexpressing oesophageal cancer does not improve disease-free survival, a phase III trial shows.
Although the monoclonal antibody did not lead to increased toxicities, the US researchers say the results highlight the need to continue evaluating new combinations of human epidermal growth factor receptor 2 (HER2)-directed therapies.
Writing in The Lancet Oncology, the team randomly assigned 203
